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Open access under CC BY-NC-ND license.An apology for beta blockersmight have stumbled across other rather informative (and much
We read with interest the recent review on beta-blockers in cir-
rhosis by Ge and Runyon [1]. This topic is of great importance, as
non-selective beta blockers are a pharmacological mainstay in
the management of patients with cirrhosis; the amount of evi-
dence has been increasing substantially since the ﬁrst published
trial of their use in the prevention of variceal bleeding [2], partic-
ularly in recent years.
In their review, the authors dedicate a sub-heading to ‘‘Beneﬁts
of beta-blocker therapy’’. This consists of only two paragraphs, in
which some trials of beta blockade for primary prevention of vari-
ceal bleeding are discussed. In the last line, the use of beta blockers
in secondary prophylaxis of variceal bleeding is just about men-
tioned, and reference to a table (Table 1) is made. Table 1, titled
‘‘Key studies supporting beta-blocker usage’’, only lists trials of
beta blockers for the primary prevention of variceal bleeding. For
reasons best known to them (but not to us), the authors chose to
completely ignore mountains of evidence for a wide range of
non-selective beta blockers in patients with cirrhosis, including
such trivialities as effects on mortality, risk of decompensation,
development of ascites, renal failure, encephalopathy, and bacte-
rial infections. This includes true landmark studies [3], the results
ofwhichhavebothbeen replicated [4] andextensivelydiscussed in
the literature [5]. Similarly, the vast majority of the wide-ranging
pharmacological effects of beta-blockers, particularly non-haemo-
dynamic effects [5,6], are largely ignored, exceptionmade for a sin-
gle mentioning of bacterial translocation in Fig. 1.
The authors then embark on a lengthy discussion of ‘‘adverse
effects of beta-blocker therapy’’. The sub-heading itself spans 5
paragraphs (more than twice the length of the beneﬁts!), but the
successive elaboration on the inherent evil of beta blockers (vari-
ously termed ‘‘The differential effect of beta-blockers in cirrhosis’’,
‘‘Blood pressure and survival’’, ‘‘Beta-blockers in refractory
ascites’’, and ‘‘Additional challenges of beta-blocker therapy’’)
cover several pages. In this section, the authors discuss at length
the possible adverse effects of beta blockers, quoting studies in
patients without liver disease published mainly between 1969
and 1990. It is also rather puzzling that the use of beta blockers
in arterial hypertension, cardiac failure, and acute coronary syn-
dromes is discussed, as this debate has little importance to their
use in liver disease. Interestingly, had the authors applied a bit
more dedication to their ‘‘holistic’’ approach to beta-blockers, theyJournal of Hepatology 2more recent) studies outlining the safety (and signiﬁcant beneﬁt)
of beta blockers in COPD [7,8], peripheral vascular disease [9],
and diabetes [10]. Table 2, titled ‘‘Key studies suggesting potential
harm from beta-blocker usage’’ clearly is meant to mirror Table 1
in size and importance. It strikes us that of the ‘‘key’’ studies men-
tioned in this table, the ﬁrst only shows an increased likelihood of
adverse events with beta blockers as compared to placebo (a ﬁnd-
ing which is hardly surprising), while the second study quite
amusingly only investigates the prognostic importance of the
cardiac index in cirrhosis without making use of beta blockers.
The other two quoted studies are a heavily debated observational
study and a cross-over study looking at paracentesis-induced
circulatory dysfunction in 10 patients. By contrast, even the com-
pletely unrepresentative choice of key studies in Table 1 entirely
consists of controlled trials.
At this point it is of little further consequence to mention
other surprising ﬁndings, such as the space given to the discus-
sion of midodrine and ACE inhibitors in a review on beta blockers,
and the fact that studies on midodrine are quoted as evidence
‘‘conﬁrming the importance of maintaining cardiac output in
patients with advanced cirrhosis’’ – indeed, midodrine is a vaso-
constricting agent and does not increase cardiac output, but has
actually been found to decrease it [11].
Finally, in their fervour against beta-blockers, the authors go
as far as providing ‘‘recommendations’’ for the use of beta block-
ers in cirrhosis, the evidence for which is as feeble as the discus-
sion leading up to it. Needless to say, these are to our mind very
hazardous statements, which might well lead to a reduction in
the use of this class of highly effective and very cheap agents,
which have rightly been termed ‘‘the Hepatologist’s Aspirin’’ [12].
Sadly, we feel that a great opportunity to discuss this crucial
topic in Hepatology has been missed, as this review is
ill-conceived and poorly researched, leading to conclusions which
might be far more harmful than any effect beta blockers might
have in patients with cirrhosis.
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Beta-blockers in cirrhosis: Thank you for your attention
To the Editor:
We graciously thank Drs. Ferrarese, Thalheimer, their colleagues,
and the editorial board and worldwide readership of the Journal
of Hepatology for their interest in our article [1]. We are humbled
and honored by the international attention that our article has
received, and are excited by the debate that it has ignited within
the hepatology community. We have received numerous positive
correspondences regarding our review [2]. In light of recent
studies that have stirred controversy, and in anticipation of
future studies that will continue to stir controversy, we believed
a fresh objective look at the emerging evidence in the use of
beta-blockers in cirrhosis was warranted.
At our institution, our chief executive ofﬁcer frequently
impresses his mantra to ‘‘put patients ﬁrst’’ upon our entire
hospital staff [3]. As physicians, we all believe that what comes
ﬁrst is our relentless and selﬂess service and dedication to
our patients. Sometimes, this involves challenging existing
treatments when they are later found to be harmful, such as
when the same investigator who ﬁrst studied the beneﬁts of
beta-blockers in patients with cirrhosis no longer found these
beneﬁts universally applicable [4].
We have frequently cared for patients with advanced cirrhosis
who were seemingly harmed by beta-blockers once they had
fallen outside a certain ‘‘therapeutic window’’ (that had only
recently been hypothesized) [5]. Once their beta-blockers were
discontinued, azotemia, hypotension, and acute kidney injury
frequently and convincingly resolved. We were certain other
clinicians around the world must have encountered similar
experiences, yet the scientiﬁc evidence appeared to be lacking.
How could we turn our back on 30 years of highly cited landmark
studies that promoted the use of beta-blockers? Did we miss
something that was actually harming our patients?
Our article was therefore inspired by a need to re-explore the
data. We do not dispute that the beneﬁts of beta-blockers have
been well-documented in patients with cirrhosis; however, that
was not the focus of our article. We acknowledged these existing
beneﬁts and set out to more closely examine the studies that had
been ignored [6], forgotten [7], or downplayed [8,9]. What we
found was evidence – the quality of which can be debated, but
nonetheless evidence stemming from astute clinicians making
clinical observations – that beta-blockers were perhaps not as
universally indicated as even we ourselves had previously
believed. Just as the acetylsalicylic acid of cardiology has its
limitations, the ‘‘aspirin of hepatology’’ appears to have its own
pitfalls and limitations.
Even now, as this debate re-emerges, a new study from
Mandorfer and colleagues provides fresh evidence demonstrating
the detrimental effect of beta-blocker treatment after the
development of spontaneous bacterial peritonitis [10]. More
studies and debate are certain to follow.
We are extremely pleased that our review has achieved its
intended effect of renewing dialogue and reopening the scrutiny
on beta-blockers. We hope that this dialogue, along with new
research speciﬁcally focusing at studying the end-stages of
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